Precision BioSciences’ (DTIL) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL) in a research note released on Wednesday,Benzinga reports. They currently have a $60.00 target price on the stock.

Separately, BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a research report on Friday, January 10th.

Precision BioSciences Price Performance

Shares of Precision BioSciences stock opened at $5.01 on Wednesday. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The company’s 50-day moving average price is $5.13 and its two-hundred day moving average price is $6.78. Precision BioSciences has a 52 week low of $3.61 and a 52 week high of $15.97. The stock has a market cap of $38.43 million, a PE ratio of 83.51 and a beta of 1.59.

Insiders Place Their Bets

In other Precision BioSciences news, insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total transaction of $49,274.73. Following the sale, the insider now owns 87,440 shares in the company, valued at approximately $418,837.60. The trade was a 10.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $4.67, for a total value of $172,033.46. Following the sale, the chief executive officer now owns 107,087 shares in the company, valued at approximately $500,096.29. The trade was a 25.60 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have purchased 8,734 shares of company stock worth $39,946 and have sold 47,279 shares worth $222,064. Corporate insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On Precision BioSciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Commonwealth Equity Services LLC purchased a new position in Precision BioSciences during the 4th quarter valued at about $48,000. Samalin Investment Counsel LLC purchased a new position in Precision BioSciences during the 4th quarter valued at about $59,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Precision BioSciences by 22.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 15,534 shares of the company’s stock valued at $59,000 after acquiring an additional 2,805 shares in the last quarter. XTX Topco Ltd purchased a new position in Precision BioSciences during the 4th quarter valued at about $67,000. Finally, Jane Street Group LLC purchased a new position in Precision BioSciences during the 4th quarter valued at about $146,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.